Content area
Full text
Introduction
Ovarian cancer (OC), a tumor which develops in ovaries, is the most deathful gynecologic tumor with 10-year survival rate being ≤21% (Jelovac and Armstrong, 2011; Kalavska et al., 2018). Although great efforts have been made to overcome OC, >150,000 patients are died of OC every year (Di Lorenzo et al., 2018). There are many risk factors of OC, such as long period of ovulation (Kuznia and Roett, 2015), genetics (Norquist et al., 2016), age (Gibson et al., 2016), smoking (Jeon et al., 2016) and so on. At early stage of OC, there is no specific symptom (Kuznia and Roett, 2015). However, OC patients at late stage may suffer from many discomforts, such as abdominal pain, pelvic pain, early satiety and so on (Kuznia and Roett, 2015). Chemotherapy is usually employed for general standard of OC care. Doxorubicin (as called adriamycin) belongs to anthracycline family and is one of chemotherapeutic agents often used for OC therapy. Doxorubicin can interfere with the function of topoisomerase II and then leads to cytotoxicity to tumor cells (Bodley et al., 1989). Despite doxorubicin’s efficacy, doxorubicin resistance often occurs during the clinical treatment of OC and lead to chemotherapy failure. Hence, there is an urgent need to explore the mechanisms related to chemotherapy resistance of OC.
CCL20, also called LARC or MIP3A, is one of small cytokines and plays key roles in the development of various cancers, such as prostate cancer, breast cancer and so on (Beider et al., 2009; Kim et al., 2009). Moreover, Ignacio et al found that NF-κB-medicated CCL20 upregulation was involved in CXCR2-Driven OC development (Ignacio et al., 2016). Son et al indicated that CCL20 may be one of the novel therapeutic targets for OC (Son et al., 2013). However, the relationship between CCL20 expression and chemotherapy resistance of OC has yet to be studied.
Here, we established doxorubicin-resistant SKOV3 DR cells from SKOV3 cells via 6-month continuous treatment with gradient concentrations of doxorubicin. Quantitative PCR (qPCR) and Western blot analysis found that CCL20 mRNA and protein expression were enhanced in SKOV3 DR cells compared to that in SKOV3 cells. In the other hand, doxorubicin enhanced CCL20 expression in SKOV3 cells at time- and dose-dependent manner....